|
1
|
Instituto Nacional de Câncer - INCA.
Brasília: Ministério da Saúde; Estimativa 2012: Incidência de
Câncer no Brasil. Available at: http://www.inca.gov.br/estimativa/2012/estimative20122111.pdf.
|
|
2
|
Matysiak-Budnika T and Mégraudb F: H.
pylori infection and gastric cancer. Eur J Cancer. 42:708–716.
2006. View Article : Google Scholar
|
|
3
|
Wen S and Moss SF: H. pylori
virulence factors in gastric carcinogenesis. Cancer Lett. 282:1–8.
2009. View Article : Google Scholar
|
|
4
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Correa P and Houghton J: Carcinogenesis of
Helicobacter pylori. Gastroenterology. 133:659–672.
2007.
|
|
6
|
Shin CM, Kim N, Lee HS, Lee DH, Kim JS,
Jung HC and Song IS: Intrafamilial aggregation of gastric cancer: a
comprehensive approach including environmental factors,
Helicobacter pylori virulence, and genetic susceptibility.
Eur J Gastroenterol Hepatol. 23:411–417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueda K, Cornwell MM, Gottesman MM, Pastan
I, Roninson IB, Ling V and Riordan JR: The MDR1 gene, responsible
for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys
Res Commun. 141:956–962. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Helvoort A, Smith AJ, Sprong H,
Fritzsche I, Schinkel AH, Borst P and van Meer G: MDR1
P-glycoprotein is a lipid translocase of broad specificity, while
MDR3 P-glycoprotein specifically translocates phosphatidylcholine.
Cell. 87:507–517. 1996.PubMed/NCBI
|
|
9
|
Dey S: Single nucleotide polymorphisms in
human P-glycoprotein: its impact on drug delivery and disposition.
Expert Opin Drug Deliv. 3:23–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thörn M, Finnström N, Lundgren S, Rane A
and Lööf L: Cytochromes P450 and MDR1 mRNA expression along the
human gastrointestinal tract. Br J Clin Pharmacol. 60:54–60.
2005.PubMed/NCBI
|
|
11
|
Willingham MC, Cornwell MM, Cardarelli CO,
Gottesman MM and Pastan I: Single cell analysis of daunomycin
uptake and efflux in multidrug-resistant and -sensitive KB cells:
effects of verapamil and other drugs. Cancer Res. 46:5941–9546.
1986.PubMed/NCBI
|
|
12
|
Thiebaut F, Tsuruo T, Hamada H, Gottesman
MM, Pastan I and Willingham MC: Cellular localisation of the
multidrug-resistance gene product P-glycoprotein in normal human
tissues. Proc Natl Acad Sci USA. 84:7735–7738. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jäeger W: Classical resistance mechanisms.
Int J Clin Pharmacol Ther. 47:46–48. 2009.PubMed/NCBI
|
|
14
|
Ho GT, Moodie FM and Satsangi J: Multidrug
resistance 1 gene (Pglycoprotein170): an important determinant in
gastrointestinal disease? Gut. 52:759–766. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paule B, Castagne V, Picard V, Saffroy R,
Adam R, Guettier C, Farinotti R and Bonhomme-Faivre L: MDR1
polymorphism role in patients treated with cetuximab and irinotecan
in refractory colorectal cancer. Med Oncol. 27:1066–1072. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugimoto M, Furuta T, Shirai N, et al:
MDR1 C3435T polymorphism has no influence on developing
Helicobacter pylori infection-related gastric cancer and
peptic ulcer in Japanese. Life Sci. 83:301–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tahara T, Arisawa T, Shibata T, Hirata I
and Nakano H: Multi-drug resistance 1 polymorphism is associated
with reduced risk of gastric cancer in the Japanese population. J
Gastroenterol Hepatol. 22:1678–1682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taheri M, Mahjoubi F and Omranipour R:
Effect of MDR1 polymorphism on multidrug resistance expression in
breast cancer patients. Genet Mol Res. 9:34–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Turgut S, Turgut G and Atalay EO: Genotype
and allele frequency of human multidrug resistance (MDR1) gene
C3435T polymorphism in Denizli province of Turkey. Mol Biol Rep.
33:295–300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rao DN, Anuradha C, Vishnupriya S, Sailaja
K, Surekha D, Raghunadharao D and Rajappa S: Association of an MDR1
gene (C3435T) polymorphism with acute leukemia in India. Asian Pac
J Cancer Prev. 11:1063–1066. 2010.PubMed/NCBI
|
|
21
|
Jamroziak K, Balcerczak E, Cebula B, et
al: Multi-drug transporter MDR1 gene polymorphism and prognosis in
adult acute lymphoblastic leukemia. Pharmacol Rep. 57:882–888.
2005.PubMed/NCBI
|
|
22
|
Schwab M, Schaeffeler E, Marx C, et al:
Association between the C3435T MDR1 gene polymorphism and
susceptibility for ulcerative colitis. Gastroenterology. 124:26–33.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sabahi Z, Salek R, Heravi RE, et al:
Association of gastric cancer incidence with MDR1 gene polymorphism
in an ethnic Iranian population. Indian J Cancer. 47:317–321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balram C, Sharma A, Sivathasen C and Lee
EJ: Frequency of C3435T single nucleotide MDR1 genetic polymorphism
in an Asia population: phenotypic-genotypic correlates. Br J Clin
Pharmacol. 56:78–83. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE,
Calcagno AM, Ambudkar SV and Gottesman MM: A ‘silent’ polymorphism
in the MDR1 gene changes substrate specificity. Science.
315:525–528. 2007.
|
|
26
|
Mizuarai S, Aozasa N and Kotani H: Single
nucleotide polymorphisms result in impaired membrane localization
and reduced atpase activity in multidrug transporter ABCG2. Int J
Cancer. 109:238–246. 2004. View Article : Google Scholar
|
